Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 23-year-old is using 2.5 mg dutasteride, 5 mg oral minoxidil, RU58841, a laser cap, and PRF injections for hair loss. They are hesitant about microneedling due to concerns about RU58841 absorption and are considering other treatments.

The user shared their two-year progress using finasteride, noting hair stabilization without side effects and no use of minoxidil. They plan a hair transplant and emphasize finasteride's role in maintaining hair rather than regrowing it.

Hair fibers can effectively cover thinning hair when used with minoxidil and hairspray but require daily application and can be inconvenient in certain conditions. Some users prefer treatments like finasteride, dutasteride, microneedling, or wigs due to the maintenance and limitations of hair fibers.

A 32-year-old man from Vietnam, at Norwood 7 hair loss, is using Minoxidil, Finasteride, rosemary oil, NMN, and CoQ10 to regrow hair. Despite minor improvements, alternatives like hair systems or accepting baldness are suggested due to advanced hair loss.

PP405 is discussed as a potential hair loss treatment, with doubts about its effectiveness and availability. Users mention using finasteride and minoxidil, and express concerns about PP405's cost and market release.

Dutasteride is preferred over finasteride for hair loss due to fewer side effects. Combining dutasteride with minoxidil and RU58841 is effective for hair regrowth, even during steroid use.

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

The conversation covers aggressive hair regrowth treatments like Dutasteride, Minoxidil (oral and topical), RU58841, microneedling, and ketoconazole shampoo. It also mentions PRP, laser therapy, GHK-Cu injections, and hormone therapy for maximum regrowth.

A user reversed hair loss using 10% sulfur soap, which reduced scalp inflammation and possibly demodex mites. The user did not use finasteride or minoxidil, suggesting inflammation may contribute to hair loss.

A user switched from finasteride to dutasteride, experiencing significant shedding initially but noticing improved hair health and thickness over time. They also use minoxidil, both oral and topical, and report no significant side effects from the treatments.

The conversation discusses hair regrowth using minoxidil and dutasteride, with users sharing their experiences and results. Some users report improvements, while others mention side effects like low libido and erectile dysfunction.

Dutasteride is likely the most effective treatment for male pattern baldness, followed by finasteride and minoxidil in various forms and dosages. Users discuss personal experiences, dosages, and potential side effects, with some considering combining treatments for better results.

The conversation discusses various hair loss treatments, with some users avoiding finasteride due to potential side effects and opting for alternatives like dermarolling, minoxidil, peppermint oil, and other natural remedies. Despite trying different supplements and oils, many users report limited success, with some eventually considering or using finasteride, dutasteride, or topical treatments for better results.

Dutasteride at 0.5mg may have fewer sexual side effects than expected, with many side effects attributed to psychological factors (nocebo effect). The placebo group experienced more side effects, suggesting fear and anxiety might contribute to perceived side effects.

Finasteride and minoxidil are recommended as first-line treatments for hair loss, with dutasteride and oral minoxidil as stronger options if needed. Hair transplants should only be considered after achieving stability with medication, and non-surgical options are suggested if medications are ineffective.

An 18-year-old is using a high-dose hair loss treatment with 40mg daily dutasteride, finasteride, minoxidil, tretinoin, and topical bicalutamide. Despite health risk concerns, especially liver issues, they report hair regrowth progress and intend to continue the regimen.

Hair transplants can initially yield good results, but native hair is more reliable, and transplanted hair may still be lost over time. Early intervention with treatments like topical finasteride and minoxidil is recommended, but it's important to start with lower doses and manage expectations realistically.

Injectable AHK-Cu is being explored for hair growth, with some users noting skin benefits but expressing concerns about unwanted body hair growth. Topical application is more common, and users discuss mixing it with hyaluronic acid serum at a 1% concentration.

A user shared their experience using 2-deoxy-D-ribose (2dDR) for hair regrowth, noting early positive results without side effects, alongside their long-term use of minoxidil and finasteride. They mentioned 2dDR's potential effectiveness in boosting blood flow to hair follicles and its availability online.

Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.